Ethics guidelines strengthened but reach remains limited

Eggertson, Laura
February 2009
CMAJ: Canadian Medical Association Journal;2/17/2009, Vol. 180 Issue 4, p379
Academic Journal
The article focuses on the updated draft of ethics guidelines governing human research which was issued by the granting councils in Canada. It notes that the draft includes the expanded sections on aboriginal and qualitative research, and the chapters on genetic and human-tissue research and clinical trials. While some researchers praise the changes on the guidelines, it states that others believe that the alterations do not adequately address the problems related to the transition of health research from research-based institutions into community settings. Canada's Tri-Council policy which articulates ethical principles concerning researches which involves humans is also discussed.


Related Articles

  • Understanding global transition assessments. Wyrwich, Kathleen W.; Tardino, Vicki M. // Quality of Life Research;Aug2006, Vol. 15 Issue 6, p995 

    Objective: Several methods currently used for determining meaningful or important change in health-related quality of life (HRQoL) measures are anchored by global transition items. It can be empirically demonstrated that patients' responses to these gold standards for change do not...

  • Clinical trials: chasing recruits.  // CMAJ: Canadian Medical Association Journal;2/17/2009, Vol. 180 Issue 4, p375 

    The article focuses on the recruitment of research participants for the clinical studies in Canada. The U.S. Officer of the Inspector General states that the disturbing recruitment practices for clinical participants have been developed because of the increasingly commercial clinical trial...

  • They're Dying to Get In. Bjerklie, David // Time;4/22/2002, Vol. 159 Issue 16, p56 

    Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects...

  • CHAPTER 26: Design Principles and Their Application in Preventive Field Trials. Brown, C. Hendricks // Handbook of Drug Abuse Prevention: Theory, Science, & Practice;2003, p523 

    The article provides a framework for assessing the quality of a preventive field trial. Such a framework is useful for three purposes. First, research scientists can direct their attention to a limited number of essential elements in designing and implementing new preventive trials. Second,...

  • Blinding in clinical trials and other studies. Day, Simon J; Altman, Douglas G // BMJ: British Medical Journal (International Edition);08/19/2000, Vol. 321 Issue 7259, p504 

    Discusses the relevance of allocation concealment, or blinding, in clinical trial practice. Importance of blinding in trials when response criteria is subjective; Difficulties involved in conducting double blind trials; Risk of bias associated with inadequate blinding; Use of blinding in other...

  • Retaining Subjects Is Harder Than Recruiting Them. Engfer, Doug // Applied Clinical Trials;Oct2004, Vol. 13 Issue 10, p70 

    The article discusses the difficulty of retention in contrast with recruitment of subjects in clinical trials in the U.S. Percentage of retention rates and dropout rates; Potential benefits of improving retention; Importance of communication and education between the researcher and the subject;...

  • Better standards for better reporting of RCTs. Bossuyt, Patrick M M // BMJ: British Medical Journal (International Edition);06/02/2001, Vol. 322 Issue 7298, p1317 

    Editorial. Discusses the need to improve standards for better reporting of randomized controlled trials (RCT). Development of the consolidated standards of reporting trials (CONSORT) statement; Changes made in the design of the CONSORT; Reasons for the changes.

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics